Accuray (Sunnyvale, California) reported that FDA has granted it 510(k) clearance to market its Dose Control System (DCS), a new feature for Accuray's TomoTherapy device that is said to improve system performance.

Cigna (Bloomfield, Connecticut) and HealthSpring (Nashville, Tennessee) said that it signed a definitive agreement under which Cigna will acquire all the outstanding shares of HealthSpring for $55 per share in cash, a 37% premium over last week's closing stock price, representing a total transaction value of $3.8 billion.

Medtronic (Minneapolis) could be one step closer in its bid to have drug eluting stents (DES) treat erectile dysfunction. Last week, the med-tech giant reported that it had completed its ZEN (Zotarolimus-Eluting Peripheral Stent System for the Treatment of Erectile Dysfunction in Males with Sub-Optimal Response to PDE5 Inhibitors), feasibility study.

Cook Medical (Bloomington, Indiana) reported that its Evolution Duodenal Controlled-Release Stent was recently granted FDA clearance. The company said that this new stent expands palliative care options for patients and offers these patients a minimally invasive alternative to relieve the symptoms and potentially life-threatening complications resulting from duodenal obstruction, such as abdominal pain, vomiting, malnutrition and aspiration.

Results from the PREVENT-SCD (PRospective EValuation of VENtricular Tachyarrhythmic Events and Sudden Cardiac Death in Patients with Left Ventricular Dysfunction)trial, published in the journal Clinical Research Cardiology, reinforce the use of Cambridge Heart's (Tewksbury, Massachusetts) test to identify patients at risk of Sudden Cardiac Death (SCD). (Medical Device Daily)